{"ticker": {"uuid": "62392bd1-8921-4120-a935-b80f1ed83297", "symbol": "TMO", "name": "Thermo Fisher Scientific Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "summary": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize ", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T23:16:37+00:00", "published_display": "12 Aug 2026 23:16", "sentiment": "neutral", "sentiment_pct": 51, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.302, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Guidance", "Healthcare", "Manufacturing", "Net Income"]}, {"title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T22:09:52+00:00", "published_display": "12 Aug 2026 22:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.491, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Healthcare", "Share Price", "Shareholder"]}, {"title": "Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist", "summary": "The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, and a strong track record of operational value creation. Dirk Bontridder has been appointed Chief Executive Officer to lead the company through its next stage of growth, in partnership with Astorg. LUXEMBOURG & NEW YORK & PARIS, August 12, ", "url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:10:00+00:00", "published_display": "12 Aug 2026 12:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.411, "duplicate_count": 1, "topics": ["Diagnostics", "Healthcare", "M A", "Pharmaceuticals", "Shareholder"]}, {"title": "Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg", "summary": "WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher'", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-completes-sale-120000581.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:00:00+00:00", "published_display": "12 Aug 2026 12:00", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.456, "duplicate_count": 1, "topics": ["Diagnostics", "M A", "Pharma"]}, {"title": "Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030", "summary": "Company Logo Accelerating momentum across major industry heavyweights\u2014highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance\u2014is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics MarketBiophotonics Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"Biophotonics - A G", "url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:20:00+00:00", "published_display": "12 Aug 2026 11:20", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.454, "duplicate_count": 1, "topics": ["Biophotonics", "Growth Rate", "Healthcare", "Imaging", "Market Research Reports", "Medical Diagnostics"]}, {"title": "Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?", "summary": "Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Growth Machine Bu", "url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T21:20:06+00:00", "published_display": "11 Aug 2026 21:20", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.369, "duplicate_count": 1, "topics": ["Acquisitions", "Balance Sheet", "Clinical Trials", "Earnings", "Earnings Growth", "Guidance"]}, {"title": "Talen Energy (TLN) Raised Guidance In August, So Why The Loss?", "summary": "On August 5, Talen Energy (NASDAQ:TLN) posted a net loss for the second quarter, and yet the same release raised the company's full-year 2026 outlook and lifted its expectations for 2027 and 2028. That looks like a contradiction until you separate the accounting from the cash. One line tells you what hit the income statement. The other tells you where the business is actually headed.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Flywheel Strategy Gaining Speed Adjusted EBITDA came in at $374 million for the quarter, up sharply from $90 million a year earlier,", "url": "https://finance.yahoo.com/markets/stocks/articles/talen-energy-tln-raised-guidance-192349215.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:23:49+00:00", "published_display": "11 Aug 2026 19:23", "sentiment": "negative", "sentiment_pct": 43, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.485, "duplicate_count": 1, "topics": ["Balance Sheet", "Earnings", "Energy", "Guidance", "Share Buyback"]}, {"title": "Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson\u2019s Precision Medicine", "summary": "Olink\u2122 Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using Olink technology. Access: The resulting data are available to researchers in PPMI's repository. Purpose: The dataset may help researchers study Parkinson's biology, patient subtypes, disease progression and potential biomarkers. Impact: The resource supports prec", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:30:00+00:00", "published_display": "11 Aug 2026 12:30", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.25, "duplicate_count": 1, "topics": ["Biomarkers", "Neurodegenerative Disease", "Parkinsons Disease", "Precision Medicine", "Proteomics"]}, {"title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "summary": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T08:45:00+00:00", "published_display": "11 Aug 2026 08:45", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.275, "duplicate_count": 1, "topics": ["Biotech", "Gene Therapy", "Growth Rate", "Market Research Reports", "Market Research", "Pharmaceuticals"]}, {"title": "Thermo Fisher VP Holmes sells $245,620 in TMO stock By Investing.com", "summary": "", "url": "", "source_name": "Investing.com Canada", "published_at": "2026-08-10T20:19:26+00:00", "published_display": "10 Aug 2026 20:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.304, "duplicate_count": 1, "topics": []}, {"title": "Sector Update: Healthcare Stocks Gain Late Afternoon", "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T19:58:04+00:00", "published_display": "10 Aug 2026 19:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.273, "duplicate_count": 1, "topics": ["Biotech", "Healthcare"]}, {"title": "How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform", "summary": "In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S, Thermo Fisher is deepening its role in linking high-complexity diagnostics with streamlined lab workflows and more standardized ", "url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T19:15:08+00:00", "published_display": "10 Aug 2026 19:15", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.34, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Fda Approval", "Life Sciences", "Oncology", "Revenue Growth"]}, {"title": "Sector Update: Healthcare Stocks Rise in Afternoon Trading", "summary": "Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:40:31+00:00", "published_display": "10 Aug 2026 17:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.269, "duplicate_count": 1, "topics": []}, {"title": "Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus", "summary": "Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. economic outlook, expectations for a supportive Federal Reserve policy environment and easing concerns about inflation. Strong corporate earnings also helped reinforce confidence in the market's growth prospects. Technology and growth-oriented sectors led the advance, boosting the Nasdaq, while broader participation suppo", "url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:34:00+00:00", "published_display": "10 Aug 2026 12:34", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.324, "duplicate_count": 1, "topics": ["Dividends", "Earnings", "Earnings Estimate", "Earnings Growth", "Healthcare", "Tech"]}, {"title": "Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?", "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher's (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?Top Long-Term Biotechnology Stocks", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T00:01:31+00:00", "published_display": "10 Aug 2026 00:01", "sentiment": "positive", "sentiment_pct": 87, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.355, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Fourth Quarter", "Guidance", "Healthcare", "Institutional Investors"]}], "by_tier": {"direct": [{"title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "summary": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize ", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T23:16:37+00:00", "published_display": "12 Aug 2026 23:16", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 51, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.302, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Guidance", "Healthcare", "Manufacturing", "Net Income"]}, {"title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T22:09:52+00:00", "published_display": "12 Aug 2026 22:09", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.491, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Healthcare", "Share Price", "Shareholder"]}, {"title": "Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist", "summary": "The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, and a strong track record of operational value creation. Dirk Bontridder has been appointed Chief Executive Officer to lead the company through its next stage of growth, in partnership with Astorg. LUXEMBOURG & NEW YORK & PARIS, August 12, ", "url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:10:00+00:00", "published_display": "12 Aug 2026 12:10", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.411, "duplicate_count": 1, "topics": ["Diagnostics", "Healthcare", "M A", "Pharmaceuticals", "Shareholder"]}, {"title": "Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg", "summary": "WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher'", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-completes-sale-120000581.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:00:00+00:00", "published_display": "12 Aug 2026 12:00", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.456, "duplicate_count": 1, "topics": ["Diagnostics", "M A", "Pharma"]}, {"title": "Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030", "summary": "Company Logo Accelerating momentum across major industry heavyweights\u2014highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance\u2014is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics MarketBiophotonics Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"Biophotonics - A G", "url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:20:00+00:00", "published_display": "12 Aug 2026 11:20", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.454, "duplicate_count": 1, "topics": ["Biophotonics", "Growth Rate", "Healthcare", "Imaging", "Market Research Reports", "Medical Diagnostics"]}, {"title": "Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?", "summary": "Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Growth Machine Bu", "url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T21:20:06+00:00", "published_display": "11 Aug 2026 21:20", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.369, "duplicate_count": 1, "topics": ["Acquisitions", "Balance Sheet", "Clinical Trials", "Earnings", "Earnings Growth", "Guidance"]}, {"title": "Talen Energy (TLN) Raised Guidance In August, So Why The Loss?", "summary": "On August 5, Talen Energy (NASDAQ:TLN) posted a net loss for the second quarter, and yet the same release raised the company's full-year 2026 outlook and lifted its expectations for 2027 and 2028. That looks like a contradiction until you separate the accounting from the cash. One line tells you what hit the income statement. The other tells you where the business is actually headed.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Flywheel Strategy Gaining Speed Adjusted EBITDA came in at $374 million for the quarter, up sharply from $90 million a year earlier,", "url": "https://finance.yahoo.com/markets/stocks/articles/talen-energy-tln-raised-guidance-192349215.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:23:49+00:00", "published_display": "11 Aug 2026 19:23", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 43, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.485, "duplicate_count": 1, "topics": ["Balance Sheet", "Earnings", "Energy", "Guidance", "Share Buyback"]}, {"title": "Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson\u2019s Precision Medicine", "summary": "Olink\u2122 Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using Olink technology. Access: The resulting data are available to researchers in PPMI's repository. Purpose: The dataset may help researchers study Parkinson's biology, patient subtypes, disease progression and potential biomarkers. Impact: The resource supports prec", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:30:00+00:00", "published_display": "11 Aug 2026 12:30", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.25, "duplicate_count": 1, "topics": ["Biomarkers", "Neurodegenerative Disease", "Parkinsons Disease", "Precision Medicine", "Proteomics"]}, {"title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "summary": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T08:45:00+00:00", "published_display": "11 Aug 2026 08:45", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.275, "duplicate_count": 1, "topics": ["Biotech", "Gene Therapy", "Growth Rate", "Market Research Reports", "Market Research", "Pharmaceuticals"]}, {"title": "Thermo Fisher VP Holmes sells $245,620 in TMO stock By Investing.com", "summary": "", "url": "", "source_name": "Investing.com Canada", "published_at": "2026-08-10T20:19:26+00:00", "published_display": "10 Aug 2026 20:19", "provider": "", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.304, "duplicate_count": 1, "topics": []}, {"title": "Sector Update: Healthcare Stocks Gain Late Afternoon", "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T19:58:04+00:00", "published_display": "10 Aug 2026 19:58", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.273, "duplicate_count": 1, "topics": ["Biotech", "Healthcare"]}, {"title": "How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform", "summary": "In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S, Thermo Fisher is deepening its role in linking high-complexity diagnostics with streamlined lab workflows and more standardized ", "url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T19:15:08+00:00", "published_display": "10 Aug 2026 19:15", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.34, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Fda Approval", "Life Sciences", "Oncology", "Revenue Growth"]}, {"title": "Sector Update: Healthcare Stocks Rise in Afternoon Trading", "summary": "Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:40:31+00:00", "published_display": "10 Aug 2026 17:40", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.269, "duplicate_count": 1, "topics": []}, {"title": "Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus", "summary": "Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. economic outlook, expectations for a supportive Federal Reserve policy environment and easing concerns about inflation. Strong corporate earnings also helped reinforce confidence in the market's growth prospects. Technology and growth-oriented sectors led the advance, boosting the Nasdaq, while broader participation suppo", "url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:34:00+00:00", "published_display": "10 Aug 2026 12:34", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.324, "duplicate_count": 1, "topics": ["Dividends", "Earnings", "Earnings Estimate", "Earnings Growth", "Healthcare", "Tech"]}, {"title": "Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?", "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher's (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?Top Long-Term Biotechnology Stocks", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T00:01:31+00:00", "published_display": "10 Aug 2026 00:01", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 87, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.355, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Fourth Quarter", "Guidance", "Healthcare", "Institutional Investors"]}], "industry": [], "sector": []}, "total_fetched": 15, "total_unique": 15, "total_relevant": 15, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 14}, "raw_articles": 14, "unique_stories": 14, "duplicates_removed": 0, "relevant_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 14, "eodhd": {"configured": true, "status": "healthy", "calls_used": 310, "call_budget": 500, "budget_used_pct": 62.0, "requests_made": 62, "last_success_at": "2026-08-13T11:15:16.589438+00:00", "newest_seen_at": "2026-08-13T11:03:51+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3184, "unmapped_mentions": 1958}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-10T20:32:36.354829+00:00", "durable_newest_article_at": "2026-08-10T20:19:26+00:00", "durable_story_count": 1}, "sentiment_summary": {"positive": 11, "negative": 2, "neutral": 2, "score": 64, "raw_score": 67, "total": 15, "evidence_count": 15, "effective_articles": 14.28, "direct_story_count": 15, "industry_story_count": 0, "sector_story_count": 0, "story_count": 15, "source_count": 2, "source_concentration": 0.8929, "direct_share": 100, "dispersion": 18, "confidence": 82, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T23:16:37+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 74, "events": [{"event": "earnings", "label": "Earnings", "weight": 3.6, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 1.8, "count": 3}, {"event": "general", "label": "Market update", "weight": 1.42, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.2, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.2, "count": 2}], "positive_events": 11, "negative_events": 2, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 14}, "raw_articles": 14, "unique_stories": 14, "duplicates_removed": 0, "relevant_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 14, "eodhd": {"configured": true, "status": "healthy", "calls_used": 310, "call_budget": 500, "budget_used_pct": 62.0, "requests_made": 62, "last_success_at": "2026-08-13T11:15:16.589438+00:00", "newest_seen_at": "2026-08-13T11:03:51+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3184, "unmapped_mentions": 1958}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-10T20:32:36.354829+00:00", "durable_newest_article_at": "2026-08-10T20:19:26+00:00", "durable_story_count": 1}}, "market_context": {"has_market_context": true, "latest_close": 594.0, "latest_week": "2026-08-07", "one_week_move": 3.4, "four_week_move": 12.7, "twelve_week_move": 35.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.200644, "market_dynamics_buy_signal": false, "relative_strength": 0.736389, "fair_value_gap": 13.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.7424, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.4% over one week, +12.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 76, "badges": ["Sentiment-trend disagreement"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 14}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 6}, {"label": "Guidance", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Market update", "count": 2}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "64/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "82/100", "tone": "positive", "text": "14.28 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "18/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+3.4% over one week, +12.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)"}], "updated_at": "2026-08-10T20:32:36.354829+00:00", "detail_intelligence": {"headline": "News confirmed by price", "summary": "Constructive news tone is drawn from 15 fresh independent stories, including 15 company-specific items across 2 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 64, "display": "64", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 82, "display": "82", "tone": "positive", "note": "high confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "15 direct stories"}, {"label": "Evidence agreement", "value": 82, "display": "82", "tone": "positive", "note": "18/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 100, "note": "14.28 effective stories"}, {"label": "Source breadth", "value": 40, "note": "2 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 74, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 82, "note": "cross-story consistency"}, {"label": "Source independence", "value": 11, "note": "lower publisher concentration"}], "freshness": 74, "source_independence": 11, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 6, "score": 69, "tone": "positive", "x": 820.6, "y": 100.4, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 4, "score": 56, "tone": "neutral", "x": 866.4, "y": 124.1, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-08-12", "label": "12 Aug", "count": 5, "score": 73, "tone": "positive", "x": 912.2, "y": 93.1, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "820.6,100.4 866.4,124.1 912.2,93.1", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Deteriorating", "tone": "negative", "recent_score": 66, "prior_score": 87, "delta": -21, "recent_count": 14, "prior_count": 1, "volume_delta": 13}, "freshness_buckets": [{"label": "Last 24 hours", "count": 4, "share": 27}, {"label": "1 to 3 days", "count": 10, "share": 67}, {"label": "4 to 7 days", "count": 1, "share": 7}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 14, "share": 93, "score": 68, "tone": "positive"}, {"label": "Investing.com Canada", "count": 1, "share": 7, "score": 58, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 6, "share": 40, "score": 68, "tone": "positive"}, {"label": "Guidance", "count": 3, "share": 20, "score": 58, "tone": "positive"}, {"label": "Deals and strategy", "count": 2, "share": 13, "score": 81, "tone": "positive"}, {"label": "Analyst action", "count": 2, "share": 13, "score": 75, "tone": "positive"}, {"label": "Market update", "count": 2, "share": 13, "score": 59, "tone": "positive"}], "topics": [{"label": "Healthcare", "count": 7, "share": 47}, {"label": "Earnings", "count": 7, "share": 47}, {"label": "Guidance", "count": 5, "share": 33}, {"label": "Diagnostics", "count": 3, "share": 20}, {"label": "Biotech", "count": 3, "share": 20}, {"label": "Shareholder", "count": 2, "share": 13}, {"label": "Pharmaceuticals", "count": 2, "share": 13}, {"label": "Market Research Reports", "count": 2, "share": 13}, {"label": "M A", "count": 2, "share": 13}, {"label": "Growth Rate", "count": 2, "share": 13}], "supporting": [{"label": "Direct evidence", "text": "15 current stories are mapped specifically to TMO."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 82/100, indicating a comparatively coherent tape."}, {"label": "Price response", "text": "Constructive news tone is being confirmed by positive weekly price action."}], "tempering": [{"label": "Source breadth", "text": "Only 2 publishers currently contribute to the measured read."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "summary": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize ", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T23:16:37+00:00", "published_display": "12 Aug 2026 23:16", "sentiment": "neutral", "sentiment_pct": 51, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.302, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Guidance", "Healthcare", "Manufacturing", "Net Income"]}, "article_count": 15, "updated_at": "2026-08-10T20:32:36.354829+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 141.5, "label": "13 Feb 2026", "close": 503.81, "index": 100.0}, {"x": 77.9, "y": 135.7, "label": "20 Feb 2026", "close": 509.91, "index": 101.2}, {"x": 113.7, "y": 126.1, "label": "27 Feb 2026", "close": 520.07, "index": 103.2}, {"x": 149.6, "y": 144.2, "label": "06 Mar 2026", "close": 500.97, "index": 99.4}, {"x": 185.4, "y": 179.5, "label": "13 Mar 2026", "close": 463.91, "index": 92.1}, {"x": 221.3, "y": 170.0, "label": "20 Mar 2026", "close": 473.92, "index": 94.1}, {"x": 257.1, "y": 170.9, "label": "27 Mar 2026", "close": 472.89, "index": 93.9}, {"x": 293.0, "y": 153.7, "label": "03 Apr 2026", "close": 490.97, "index": 97.5}, {"x": 328.8, "y": 149.3, "label": "10 Apr 2026", "close": 495.62, "index": 98.4}, {"x": 364.7, "y": 120.4, "label": "17 Apr 2026", "close": 526.08, "index": 104.4}, {"x": 400.5, "y": 174.4, "label": "24 Apr 2026", "close": 469.24, "index": 93.1}, {"x": 436.4, "y": 174.9, "label": "01 May 2026", "close": 468.74, "index": 93.0}, {"x": 472.2, "y": 178.9, "label": "08 May 2026", "close": 464.54, "index": 92.2}, {"x": 508.1, "y": 204.2, "label": "15 May 2026", "close": 437.91, "index": 86.9}, {"x": 543.9, "y": 194.8, "label": "22 May 2026", "close": 447.84, "index": 88.9}, {"x": 579.8, "y": 152.7, "label": "29 May 2026", "close": 492.02, "index": 97.7}, {"x": 615.6, "y": 171.5, "label": "05 Jun 2026", "close": 472.33, "index": 93.8}, {"x": 651.5, "y": 174.8, "label": "12 Jun 2026", "close": 468.87, "index": 93.1}, {"x": 687.3, "y": 178.8, "label": "19 Jun 2026", "close": 464.61, "index": 92.2}, {"x": 723.2, "y": 132.8, "label": "26 Jun 2026", "close": 513.03, "index": 101.8}, {"x": 759.0, "y": 122.9, "label": "03 Jul 2026", "close": 523.44, "index": 103.9}, {"x": 794.9, "y": 119.5, "label": "10 Jul 2026", "close": 527.05, "index": 104.6}, {"x": 830.7, "y": 114.3, "label": "17 Jul 2026", "close": 532.48, "index": 105.7}, {"x": 866.6, "y": 80.3, "label": "24 Jul 2026", "close": 568.26, "index": 112.8}, {"x": 902.4, "y": 74.5, "label": "31 Jul 2026", "close": 574.3, "index": 114.0}, {"x": 938.3, "y": 55.8, "label": "07 Aug 2026", "close": 594.0, "index": 117.9}], "sentiment_points": [{"x": 722.6, "y": 120.8, "label": "25 Jun 2026", "score": 55}, {"x": 725.4, "y": 117.1, "label": "26 Jun 2026", "score": 57}, {"x": 728.6, "y": 115.3, "label": "27 Jun 2026", "score": 58}, {"x": 728.9, "y": 115.3, "label": "27 Jun 2026", "score": 58}, {"x": 730.0, "y": 115.3, "label": "27 Jun 2026", "score": 58}, {"x": 732.8, "y": 117.1, "label": "27 Jun 2026", "score": 57}, {"x": 733.5, "y": 117.1, "label": "28 Jun 2026", "score": 57}, {"x": 733.7, "y": 117.1, "label": "28 Jun 2026", "score": 57}, {"x": 734.6, "y": 117.1, "label": "28 Jun 2026", "score": 57}, {"x": 738.3, "y": 119.0, "label": "28 Jun 2026", "score": 56}, {"x": 738.7, "y": 119.0, "label": "29 Jun 2026", "score": 56}, {"x": 742.6, "y": 119.0, "label": "29 Jun 2026", "score": 56}, {"x": 746.4, "y": 124.5, "label": "30 Jun 2026", "score": 53}, {"x": 755.7, "y": 126.3, "label": "02 Jul 2026", "score": 52}, {"x": 757.6, "y": 122.6, "label": "02 Jul 2026", "score": 54}, {"x": 763.7, "y": 120.8, "label": "03 Jul 2026", "score": 55}, {"x": 765.0, "y": 119.0, "label": "04 Jul 2026", "score": 56}, {"x": 775.0, "y": 119.0, "label": "06 Jul 2026", "score": 56}, {"x": 777.7, "y": 120.8, "label": "06 Jul 2026", "score": 55}, {"x": 779.7, "y": 120.8, "label": "07 Jul 2026", "score": 55}, {"x": 780.2, "y": 122.6, "label": "07 Jul 2026", "score": 54}, {"x": 792.9, "y": 122.6, "label": "09 Jul 2026", "score": 54}, {"x": 794.6, "y": 122.6, "label": "09 Jul 2026", "score": 54}, {"x": 794.8, "y": 122.6, "label": "09 Jul 2026", "score": 54}, {"x": 805.6, "y": 122.6, "label": "12 Jul 2026", "score": 54}, {"x": 808.4, "y": 122.6, "label": "12 Jul 2026", "score": 54}, {"x": 822.9, "y": 117.1, "label": "15 Jul 2026", "score": 57}, {"x": 823.1, "y": 117.1, "label": "15 Jul 2026", "score": 57}, {"x": 826.9, "y": 117.1, "label": "16 Jul 2026", "score": 57}, {"x": 838.1, "y": 119.0, "label": "18 Jul 2026", "score": 56}, {"x": 850.1, "y": 119.0, "label": "20 Jul 2026", "score": 56}, {"x": 850.2, "y": 119.0, "label": "20 Jul 2026", "score": 56}, {"x": 850.4, "y": 119.0, "label": "20 Jul 2026", "score": 56}, {"x": 851.3, "y": 120.8, "label": "21 Jul 2026", "score": 55}, {"x": 852.9, "y": 120.8, "label": "21 Jul 2026", "score": 55}, {"x": 858.1, "y": 119.0, "label": "22 Jul 2026", "score": 56}, {"x": 863.6, "y": 119.0, "label": "23 Jul 2026", "score": 56}, {"x": 864.0, "y": 117.1, "label": "23 Jul 2026", "score": 57}, {"x": 869.0, "y": 111.6, "label": "24 Jul 2026", "score": 60}, {"x": 869.7, "y": 107.9, "label": "24 Jul 2026", "score": 62}, {"x": 887.7, "y": 122.6, "label": "28 Jul 2026", "score": 54}, {"x": 902.1, "y": 120.8, "label": "30 Jul 2026", "score": 55}, {"x": 904.8, "y": 119.0, "label": "31 Jul 2026", "score": 56}, {"x": 906.7, "y": 119.0, "label": "31 Jul 2026", "score": 56}, {"x": 908.7, "y": 122.6, "label": "01 Aug 2026", "score": 54}, {"x": 913.6, "y": 122.6, "label": "02 Aug 2026", "score": 54}, {"x": 923.5, "y": 122.6, "label": "04 Aug 2026", "score": 54}, {"x": 926.8, "y": 120.8, "label": "04 Aug 2026", "score": 55}, {"x": 930.1, "y": 124.5, "label": "05 Aug 2026", "score": 53}, {"x": 934.9, "y": 122.6, "label": "06 Aug 2026", "score": 54}, {"x": 935.2, "y": 122.6, "label": "06 Aug 2026", "score": 54}, {"x": 958.0, "y": 115.3, "label": "10 Aug 2026", "score": 58}], "price_path": "42.0,141.5 77.9,135.7 113.7,126.1 149.6,144.2 185.4,179.5 221.3,170.0 257.1,170.9 293.0,153.7 328.8,149.3 364.7,120.4 400.5,174.4 436.4,174.9 472.2,178.9 508.1,204.2 543.9,194.8 579.8,152.7 615.6,171.5 651.5,174.8 687.3,178.8 723.2,132.8 759.0,122.9 794.9,119.5 830.7,114.3 866.6,80.3 902.4,74.5 938.3,55.8", "sentiment_path": "722.6,120.8 725.4,117.1 728.6,115.3 728.9,115.3 730.0,115.3 732.8,117.1 733.5,117.1 733.7,117.1 734.6,117.1 738.3,119.0 738.7,119.0 742.6,119.0 746.4,124.5 755.7,126.3 757.6,122.6 763.7,120.8 765.0,119.0 775.0,119.0 777.7,120.8 779.7,120.8 780.2,122.6 792.9,122.6 794.6,122.6 794.8,122.6 805.6,122.6 808.4,122.6 822.9,117.1 823.1,117.1 826.9,117.1 838.1,119.0 850.1,119.0 850.2,119.0 850.4,119.0 851.3,120.8 852.9,120.8 858.1,119.0 863.6,119.0 864.0,117.1 869.0,111.6 869.7,107.9 887.7,122.6 902.1,120.8 904.8,119.0 906.7,119.0 908.7,122.6 913.6,122.6 923.5,122.6 926.8,120.8 930.1,124.5 934.9,122.6 935.2,122.6 958.0,115.3", "price_change": 17.9, "sentiment_change": 3, "latest_close": 594.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}